Patents Assigned to Circular Commitment Company
  • Therapeutic biologic for treatment of hepatocellular carcinoma
    Patent number: 11485771
    Abstract: Conjugates comprising a coagulating agent conjugated to an antibody, where the antibody specifically binds an extracellular domain epitope of a mammalian PLVAP protein, and methods of using such conjugates, including methods of treating HCC by administering the conjugates or compositions thereof, such as pharmaceutical compositions.
    Type: Grant
    Filed: July 16, 2019
    Date of Patent: November 1, 2022
    Assignee: Circular Commitment Company
    Inventors: Kuo-Jang Kao, Yun-Hsin Wang
  • Methods and agents for the diagnosis and treatment of hepatocellular carcinoma
    Patent number: 11339217
    Abstract: The present invention relates to methods of diagnosing and methods of treating hepatocellular carcinoma in a subject. The invention also relates to antagonists of PLVAP proteins, such as antibodies that specifically bind PLVAP proteins, as well as compositions and kits comprising antagonists of PLVAP proteins. The invention further relates to humanized antibodies that specifically bind PLVAP protein.
    Type: Grant
    Filed: June 24, 2019
    Date of Patent: May 24, 2022
    Assignee: Circular Commitment Company
    Inventors: Kuo-Jang Kao, Andrew T. Huang
  • Therapeutic biologic for treatment of hepatocellular carcinoma
    Patent number: 10906959
    Abstract: The invention provides conjugates comprising a coagulating agent conjugated to an antibody, where the antibody specifically binds an extracellular domain epitope of a mammalian PLVAP protein. These agents specifically target HCC tumors and treat the HCC. The invention also provides methods of using these conjugates, such as methods of treating HCC by administering the conjugates provided by the invention or compositions provided by the invention, such as pharmaceutical compositions.
    Type: Grant
    Filed: August 29, 2018
    Date of Patent: February 2, 2021
    Assignee: Circular Commitment Company
    Inventors: Kuo-Jang Kao, Yun-Hsin Wang
  • Therapeutic biologic for treatment of hepatocellular carcinoma
    Patent number: 10400026
    Abstract: The invention provides conjugates comprising a coagulating agent conjugated to an antibody, where the antibody specifically binds an extracellular domain epitope of a mammalian PLVAP protein. These agents specifically target HCC tumors and treat the HCC. The invention also provides methods of using these conjugates, such as methods of treating HCC by administering the conjugates provided by the invention or compositions provided by the invention, such as pharmaceutical compositions.
    Type: Grant
    Filed: September 20, 2016
    Date of Patent: September 3, 2019
    Assignee: Circular Commitment Company
    Inventors: Kuo-Jang Kao, Yun-Hsin Wang
  • Methods and agents for the diagnosis and treatment of hepatocellular carcinoma
    Patent number: 10370445
    Abstract: The present invention relates to methods of diagnosing and methods of treating hepatocellular carcinoma in a subject. The invention also relates to antagonists of PLVAP proteins, such as antibodies that specifically bind PLVAP proteins, as well as compositions and kits comprising antagonists of PLVAP proteins. The invention further relates to humanized antibodies that specifically bind PLVAP protein.
    Type: Grant
    Filed: December 6, 2016
    Date of Patent: August 6, 2019
    Assignee: Circular Commitment Company
    Inventors: Kuo-Jang Kao, Andrew T. Huang